UNSPSC 51313433: Phenindamine hydrogen tartrate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H19N.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 28725X3PV8, chemically known as 2,3,4,9-tetrahydro-2-methyl-9-phenyl-1h-indeno(2,1-c)pyridine tartrate, but more generally known as phenindamine hydrogen tartrate, which bears US NIH Compound Identifier 11290. European Medicines Agency schedules phenindamine hydrogen tartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09764MIG.

Most nations, for tariff purposes, schedule phenindamine hydrogen tartrate under HS 29339920. SMILES: CN1CCC2=C(C1)C(C3C2CCCC3)C4CCCCC4.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51313433 Phenindamine hydrogen tartrate is a Commodity code that in practice encompasses pharmaceutical procurement by state and local health agencies, including antihistamines and related active pharmaceutical ingredients. Recent state and local solicitations under this code show demand for branded and generic pharmaceuticals, including naloxone and OTC products, supplied through established wholesaler networks and direct-to-manufacturer channels. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (MMCAP, Minnesota Department of Administration). The code reflects procurement for community health initiatives, pharmacy benefit programs, and government employee and retiree health plans across multiple jurisdictions.

Activity spans Florida, Texas, Minnesota, and Oregon, with recent opportunities showing both spot purchases and longer-term cooperative contracting. Seminole County, Florida issued an IFB (Solicitation IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, submitted electronically through the county's e-Procurement Portal. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs for state pharmacy benefit administration. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026, emphasizing price competitiveness (75 percent of evaluation weight), cGMP and Drug Supply Chain Security Act compliance, and insurance requirements up to $5,000,000 in commercial general liability.